Results 181 to 190 of about 95,392 (311)

Allogeneic hematopoietic stem cell transplantation for the treatment of chronic active Epstein-Barr virus infection. [PDF]

Cell Transplant
Wang Y, Wu J, Huang X, Xiao Y.
europepmc   +1 more source

Plerixafor alone for the mobilization and transplantation of HLA-matched sibling donor hematopoietic stem cells [PDF]

, 2019
Chen, Yi-Bin, DiPersio, John F., et al,
core   +1 more source

Tildrakizumab for the prophylaxis of graft-versus-host disease after allogeneic hematopoietic stem cell transplantation. [PDF]

Blood Adv
Runaas L, Fank S, Palen K, Szabo A, Rein LE, Ying G, Salzman N, Samanas L, Abedin S, Chhabra S, Hamadani M, Longo W, Shah NN, Haber J, Gradissimo A, Waters N, Peled JU, Johnson B, Kearl T, Drobyski WR.   +19 more
europepmc   +1 more source

Treosulfan–fludarabine conditioning in infants with severe combined immunodeficiencies: Extended study of the UK paediatric treosulfan study

British Journal of Haematology, EarlyView.
Summary Allogeneic haematopoietic stem cell transplantation (HSCT) is a curative therapy for severe combined immunodeficiency (SCID). Conditioning improves donor engraftment and freedom from immunoglobulin replacement (IgR) but increases the risks of acute and late toxicity. Treosulfan, a reduced toxicity alkylating agent, has emerged as an alternative
Su Han Lum, Sinéad Greener, Irum Latif Memon, Persis Amrolia, Zohreh Nademi, Robert Chiesa, Juliana Silva, Helen Young, Stephen Owens, Eleri Williams, Khuen Foong Ng, Terry Flood, Andrew R Gennery, Sophie Hambleton, Kanchan Rao, Mary Slatter   +15 more
wiley   +1 more source

Advances in immunotherapy for cytomegalovirus infection following allogeneic hematopoietic stem cell transplantation. [PDF]

Immunotherapy
Wang Y, Wu J, Huang X, Xiao Y.
europepmc   +1 more source

Decreased renal function predicts severe cytokine release syndrome after CAR‐T‐cell therapy for large B‐cell lymphoma

British Journal of Haematology, EarlyView.
Summary Cytokine release syndrome (CRS) remains a major toxicity of chimeric antigen receptor (CAR) T‐cell therapy in large B‐cell lymphoma (LBCL), and robust pre‐infusion predictors are needed for risk‐adapted management. We retrospectively analysed LBCL patients in the Japanese nationwide registry who underwent CD19 CAR‐T‐cell therapy between 2019 ...
Yasuyuki Arai, Tomoyasu Jo, Takayuki Sato, Masatoshi Sakurai, Daisuke Kaji, Toshio Kitawaki, Kazuyuki Shimada, Tatsu Shimoyama, Satoshi Yoshihara, Shinichi Makita, Nobuharu Fujii, Go Yamamoto, Keisuke Kataoka, Emiko Sakaida, Hideki Goto, Yasuhiro Nakashima, Akiyo Yoshida, Yoshihiro Umezawa, Haryoon Kim, Motohiro Kato, Yoshiko Atsuta, Koji Kato   +21 more
wiley   +1 more source

Long enduring response on teclistamab in a patient with myeloma relapse after allogeneic hematopoietic stem cell transplantation - a case report. [PDF]

Ann Hematol
Ebner P, Fauser J, Hetzenauer G, Köck S, Willenbacher W, Rossetti LM, Buchwald TA, Rasche L, Gunsilius E, Nachbaur D, Wolf D, Steiner N.   +11 more
europepmc   +1 more source

Improved survival with fludarabine‐based therapies in mixed phenotype acute leukaemia: A population‐based study using the WHO 2022 classification

British Journal of Haematology, EarlyView.
Summary Mixed phenotype acute leukaemia (MPAL) is a rare subtype of acute leukaemia possessing significant therapeutic challenges, as no standardized, evidence‐based treatment regimen has been defined. In this nationwide study, we aimed to assess the effect of an acute lymphoid leukaemia (ALL)‐like regimen; an acute myeloid leukaemia (AML)‐like regimen;
Lisa‐Maj Christensen, Mikkel Runason Simonsen, Jonas Faartoft Jensen, Daniel Tuyet Kristensen, Karen Dybkær, Kirsten Grønbæk, Tarec Christoffer El‐Galaly, Marianne Schmidt Ettrup, Hans Beier Ommen, Anne Louise Tølbøll Sørensen, Dennis Lund Hansen, Marianne Tang Severinsen   +11 more
wiley   +1 more source

Allogeneic Hematopoietic Stem Cell Transplantation as a Therapeutic Approach for Hereditary Diseases. [PDF]

Biomedicines
Nagieva S, Smirnikhina S.
europepmc   +1 more source

Distribution of adult T‐cell leukaemia/lymphoma subtypes and survival outcomes across geographical regions: An international retrospective cohort study

British Journal of Haematology, EarlyView.
Summary Although adult T‐cell leukaemia/lymphoma (ATL) has a higher burden in certain world regions, outcomes have not been directly compared across regions. We conducted a multicentre cohort study comparing the distribution of ATL subtypes and overall survival (OS) across 1090 adults (≥18 years) diagnosed with ATL during 2000–2023 in Japan (n = 366 ...
Bryan Valcarcel, Atae Utsunomiya, Maki Otsuka, Masaharu Miyahara, Kenji Ishitsuka, Yasushi Takamatsu, Junji Suzumiya, Kazuo Tamura, Jule F. Vasquez, Daniel Enriquez‐Vera, Brady E. Beltran, Denisse Castro, Thanya Runciman, Henry Idrobo, Elizabeth Arrieta, Oriana Arias, Eduardo Gotuzzo, Gabriela Garrido‐Pinzás, Victor Rivera, Daniel La Rosa, Camila Peña, Lorena Fiad, Juan C. Ramos, Jose Sandoval‐Sus, Alejandro Sica, Britney N. Bell, Lucy B. Cook, Veronica Leataud, Eliana C. M. Miranda, Carlos Chiattone, Hiroo Katsuya, Luis Malpica   +31 more
wiley   +1 more source